Study has reported a STING agonist MK-1454 exhibited robust tumor cytokine upregulation and effective antitumor activity in immune-competent mice-bearing tumors, and can enhance the curative effect of anti-PD1 monotherapy (26). Here, STING1 is linked to neoplasm.